NeuPath Health

NeuPath Health ROE

The Return on Equity (ROE) of NeuPath Health (NPTH.V) as of Nov 12, 2026 is -3.48 %. In the previous year, Return on Equity (ROE) was -3.40 % — a change of 2.24% (lower).

ROE

-3.48 %

YoY

2.24%

Last updated:

In 2025, NeuPath Health's return on equity (ROE) was -3.48 %, a 2.24% increase from the -3.40 % ROE in the previous year.

The NeuPath Health ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
-54.34 CAD
Jan 1, 2020
-18.31 CAD
Jan 1, 2021
-12.50 CAD
Jan 1, 2022
-19.12 CAD
Jan 1, 2023
-0.49 CAD
Jan 1, 2024
-3.40 CAD
Jan 1, 2025
-3.48 CAD
The NeuPath Health ROE history
YEARROEYoY
-3.48 %+2.24%
-3.40 %+601.04%
-0.49 %-97.46%
-19.12 %+52.93%
-12.50 %-31.71%
-18.31 %-66.31%
-54.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NeuPath Health Stock analysis

What does NeuPath Health do? NeuPath Health, Inc. generates revenue through chronic pain management services provided at its clinics in Ontario and Alberta, offering comprehensive assessments and rehabilitation for chronic pain, musculoskeletal/back injuries, sports injuries, and concussions. The company serves employers and disability insurers with workplace health services and independent medical assessments via a national network of healthcare providers. Additionally, NeuPath provides contract research services to pharmaceutical and biotechnology companies. Its healthcare providers include physiatrists, neurologists, anesthesiologists, general practitioners with specialized pain training, medication management physicians, athletic therapists, and nurses. The primary buyers of NeuPath's services are employers and disability insurers seeking workplace health solutions and independent medical evaluations. Pharmaceutical and biotechnology companies contract NeuPath for research services. The company's clinic services target patients with chronic pain conditions, while its research division serves the pharmaceutical industry. NeuPath's network spans Ontario and Alberta, with a focus on specialized medical expertise across multiple disciplines. NeuPath Health, Inc. operates a network of medical clinics delivering chronic pain management and rehabilitation services. Its national provider network supports workplace health and independent medical assessments for employers and disability insurers. The firm's contract research division works with pharmaceutical and biotechnology companies, leveraging its medical expertise in pain management and rehabilitation. The company's service mix combines direct patient care with specialized industry contracts, creating multiple revenue streams from healthcare providers and corporate clients. NeuPath Health is one of the most popular companies on Eulerpool.

ROE Details

Decoding NeuPath Health's Return on Equity (ROE)

NeuPath Health's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing NeuPath Health's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

NeuPath Health's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in NeuPath Health’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about NeuPath Health stock

Return on Equity (ROE) of NeuPath Health is -3.48 % in 2025.

Return on Equity (ROE) of NeuPath Health changed from -3.40 % to -3.48 %, representing a 2.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) NeuPath Health since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s NeuPath Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — NeuPath Health

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — NeuPath Health